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Context: High bone mass (HBM), detected in 0.2% of dual-energy x-ray absorptiometry (DXA)
scans, is characterized by raised body mass index, the basis for which is unclear.
Objective: To investigate why body mass index is elevated in individuals with HBM, we character-
izedbodycompositionandexaminedwhetherdifferences couldbeexplainedbybonephenotypes,
eg, bone mass and/or bone turnover.
Design,Setting,andParticipants:Weconductedacase-controlstudyof153caseswithunexplainedHBM
recruited from4UKcentersby screening219 088DXAscans.A totalof138 first-degree relatives (ofwhom
51 had HBM) and 39 spouses were also recruited. Unaffected individuals served as controls.
Main Outcome Measures: We measured fat mass, by DXA, and bone turnover markers.
Results:Amongwomen,fatmasswasinverselyrelatedtoageincontrols(P .01),butnotinHBMcases(P
.96) in whommean fat mass was 8.9 [95% CI 4.7, 13.0] kg higher compared with controls (fully adjusted
meandifference,P .001). Increased fatmass inmaleHBMcaseswas lessmarked (gender interactionP
.03).Comparedwithcontrols,leanmasswasalsoincreasedinfemaleHBMcases(by3.3[1.2,5.4]kg;P.002);
however, leanmass increaseswere lessmarkedthanfatmass increases, resulting in4.5%lowerpercentage
leanmass inHBMcases (P .001).Osteocalcinwasalso lower in femaleHBMcases comparedwithcontrols
(by2.8 [0.1, 5.5]g/L;P .04).Differences in fatmasswere fully attenuatedafterhipbonemineraldensity
(BMD) adjustment (P .52) but unchanged after adjustment for bone turnover (P .001), whereas the
greater hip BMD in female HBM cases wasminimally attenuated by fatmass adjustment (P .001).
Conclusions: HBM is characterized by a marked increase in fat mass in females, statistically ex-
plained by their greater BMD, but not by markers of bone turnover. (J Clin Endocrinol Metab 98:
818–828, 2013)
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Population-based studies have identified a positive as-sociation between bone mineral density (BMD) and
obesity (1–3), strongest inwomen, particularly those post-
menopausal, and sedentary individuals (1, 4). Although
increased skeletal loading by weight bearing may contrib-
ute, obesity is also positively related to BMD at non-
weight-bearing sites, suggesting the role of systemic fac-
tors. Several obesity-related endocrine factors could
theoretically stimulate bone formation, including bone-
active hormones secreted by pancreatic -cells and adi-
pocytes (5).However, causal inference fromobservational
epidemiological studies of BMDandobesity is difficult; ie,
observed relationships may instead reflect a positive in-
fluence of BMD on fat deposition. Mouse models have
suggested that bone turnover directly influences insulin
sensitivity and adiposity via a relay involving osteocalcin
(an osteoblast-specific protein) and adiponectin (pro-
duced by white adipose tissue). Reduced bone turnover,
resulting in decreased osteocalcin, has been associated
with lower adiponectin, impaired insulin sensitivity, and
increased fat deposition due to reduced energy expendi-
ture (6). Similar relationships between circulating osteo-
calcin and adiponectin, plus adiposity measures and in-
sulin sensitivity, are reported in some human populations
(7, 8). Changes in osteocalcin, induced by antiresorptive
osteoporosis treatments, affect metabolic indices and
body weight (9), although the effects of anabolic (recom-
binant human PTH) treatments on glucose homeostasis
are inconsistent (9, 10).
Population-based genetic approaches can inform
causal pathways and can examine relationships between
obesity and bone mass; however, results have been con-
flicting. First, in adolescents from the Avon Longitudinal
Study of Parents and Children (ALSPAC), a Mendelian
randomization study exploiting established genetic mark-
ers of obesity supported a causal influence of obesity on
BMD; the 2 bodymass index (BMI)-related genotypes ex-
amined gave the samepredictive effect of fatmass (FM) on
BMD,providing evidence against pleiotropy (11). Second,
within an extended family, individuals with extremely el-
evated bonemass resulting froman activatingLRP5 (low-
density lipoprotein receptor-related protein-5) mutation
had increased FM and reduced bone turnover (12), con-
sistentwithacausal influenceof reducedosteocalcinon fat
accumulation. However, LRP5 has not been linked with
obesity in the wider population (13).
Further understanding of the fat-bone relationship can
be achieved by investigating a rare and extreme popula-
tion of high bonemass (HBM) individuals.We previously
observed that HBM is a sporadic finding of generalized
raised BMD on dual-energy x-ray absorptiometry (DXA)
scanning, with a prevalence of .2% among a UK DXA-
scanned population (14). Having screened 335 115 DXA
scans across 13UKNationalHealth Service (NHS) centers
for HBM, we observed associated clinical characteristics
suggestive of a mild skeletal dysplasia, concluding that
most cases are likely to harbor as yet unidentified muta-
tions/polymorphisms increasing BMD (14). Based upon
comparison with a contemporaneous control population
(comprising unaffected first-degree relatives and spouses),
HBM cases had substantially elevated BMI, suggesting
that this extreme HBM population can be utilized to ex-
amine fat-bone relationships.
We sought to gain further insights into causal pathways
between fat and bone, exploring relationships between
BMI and bone mass in HBM individuals, using total body
(TB) DXA scanning to characterize body composition.
DXA provides a simple, quick, and low-radiationmethod
ofmeasuring3 tissue compartments (fat,mineral, and lean
mass [fat/mineral-free]) with high precision (15). Specifi-
cally, we aimed to: 1) establish whether FM is elevated in
HBMindividuals once potential confounders, eg, physical
activity (PA), are considered; 2) explore differences in age-
and gender-specific associations; and 3) investigate
whether FM changes could be explained by bone pheno-
types including BMD and/or bone turnover.
Subjects and Methods
Participant recruitment
The HBM study is a UK-based multicentered observational
study of adults with unexplained HBM. At 4 of our larger study
centers, 788 cases of unexplained HBM were identified by
screening NHS DXA databases (n  219 088). Full details of
DXA database screening and participant recruitment have pre-
viously been reported (14). In brief,HBMwasdefined as: 1) both
L1Z-score of3.2 and total hipZ-score of1.2; or 2) both
total hip Z-score  3.2 and L1 Z-score of  1.2. The first
lumbar vertebra (L1) was used because, in contrast to lower
lumbar levels, itwas not found to be associatedwith the presence
of lumbar spine osteoarthritis assessed on DXA images (14).
Caseswith significant osteoarthritis and/orother causes of raised
BMD were excluded (eg, surgical metalwork, Paget’s disease,
metastases), as were those with established diagnoses of osteo-
petrosis. A threshold of3.2 was in keeping with the only pub-
lished precedent for identifyingHBMpreviously described using
DXA (16), and most appropriately differentiated generalized
HBM fromartifact (14). Z-score rather thanT-scorewas used to
limit age bias. Index caseswere asked to pass on study invitations
to their first-degree relatives and spouses or partners. Relatives/
spouses with HBM were in turn asked to pass on study invita-
tions to their first-degree relatives and spouses. First-degree rel-
atives and spouses were recruited, in whom HBM status was
defined as summed L1 Z plus total hip Z-score of3.2. Fam-
ily-based controls comprised unaffected relatives and spouses.
All participants were clinically assessed by one doctor using a
standardized structured history and examination questionnaire,
after which TB DXA scans and (nonfasted) phlebotomy were
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performed. Routine weight and height measurements were
recorded.
Subsequently, current and lifetime PA was measured by a
short (10-min) postal questionnaire (with prepaid reply enve-
lope, sent up to 3 times) which included: 1) the short last 7-d
self-administered International PAQuestionnaire (IPAQversion
2002, http://www.ipaq.ki.se/ipaq.htm (17, 18); and 2) a histor-
ical PA questionnaire (19–21). A total of 86.5% of participants
responded and completed the PA questionnaire; those who did
not respond had similar anthropometric characteristics to those
who did (data not shown).
Recruitment ran from September 2008 until April 2010.
Written informed consent was collected for all, in line with the
Declaration of Helsinki (22). Participants were excluded if they
were aged 18 years, pregnant, or unable to provide written
informed consent for any reason.This studywas approvedby the
BathMulticenter Research Ethics Committee (REC) and at each
NHS Local REC.
DXA measurements
DXAscanswereperformedusingeitherGELunarProdigyDXA
(software version 13.2; GEHealthcare, Madison, Wisconsin) in
Birmingham, Cambridge, and Hull, or Hologic Discovery/W
DXA (software version Apex 3.0; Hologic Inc., Bedford, Mas-
sachusetts) in Sheffield. All scans were acquired and analyzed
according to each manufacturer’s standard scanning and posi-
tioning protocols. TB bone mineral content (BMC) and BMD,
FM, and lean mass (LM) were measured, together with L1 and
total hip BMD. The specific fat phenotype was measured using
android, gynoid, peripheral (arms and legs), and trunk (TB—
peripheral and head) regions of interest. All DXA images were
reviewed for quality control purposes. TB scans with metallic
artifactswere graded; this gradewas added to all boneparameter
regression models (Supplemental Table 1, published on The En-
docrine Society’s Journals Online web site at http://jcem.endo-
journals.org). Participants were centered for scanning; incom-
plete capture of soft tissue edges can introduce systematic bias
because mass is lost as body size increases. Eighty-nine (27%)
scans had evidence of incomplete capture. Hence, weighed
weight (concurrently measured using scales) and calculated
DXAweight were compared. Correlation (r2 .984) and agree-
ment (Bland-Altman rank correlation coefficient r.044, Pit-
man’s test of difference in variance P  .426 [Ref. 23]) demon-
stratednoevidenceof systematic bias.Hence, further adjustment
of analyses was not judged necessary.
Known differences in calibration exist between Hologic and
GE for all scan types (24, 25). For lumbar spine and hip scans,
systematic bias was limited by converting all measures to stan-
dardized BMD (sBMD) (26, 27). For TB, systematic differences
were limited using newly derived cross-calibration equations for
all bone and soft tissue regions of interest (25, 28) (Supplemental
Table 2). To ensure that no systematic bias was introduced by
new formulae, sensitivity analyses were performed excluding
Hologic DXA data. Lastly, because only 330 (59.5%) of 555
subjects in the originalmulticenter study population (14) hadTB
DXA scans performed, the principal characteristics of individ-
uals who received a TB DXA scan were compared to those who
did not. No differences were observed in weight, height, BMI,
sex, age, or ethnicity (data not shown).
Bone turnover markers and adiponectin
TwononfastedEDTAsampleswere collected, and serumwas
separated and frozen within 4 hours to80°C. Bone formation
(procollagen type 1 amino-terminal propeptide [P1NP], total
osteocalcin) and resorption (-C-telopeptides of type I collagen
[CTX]) markers were measured. All had inter- and intraassay
coefficients of variation6.0%across the assayworking ranges.
Electrochemiluminescence immunoassays (Roche Diagnostics,
Lewes, United Kingdom) were used to measure plasma concen-
trations of P1NP, osteocalcin, and CTX (detection limits, 4.0,
.6, and .01g/L, respectively).Total andHMW-adiponectinwas
measured using assays developed in house as previously reported
with inter- and intraassay coefficients of variation 10%across
the working range .5–30.0 mg/L (29, 30). Supplemental Table 3
provides reference ranges.
Statistical methods
Descriptive statistics are presented as mean (95% confidence
interval [CI]) for continuous data and count (percentage) for
categorical data. Analyses comparing 2 continuous variables are
presented as  coefficients and 95% CI for standardized out-
comes. Linear regression was used to analyze continuous vari-
ables, using random effects models to allow for the lack of sta-
tistical independence due to within-family clustering of
environmental factors and shared genotypes. Age, gender,
height, and menopausal status in women were considered a pri-
ori confounders of the associations between HBM status and all
DXA and bone turnover parameters. Further potential con-
founders considered in sequential regression model adjustments
included: smoking status, alcohol consumption, estrogen re-
placement therapy, history of malignancy (a proxy for current/
previous aromatase inhibitor use for breast cancer and antian-
drogens for prostate cancer as prior medication use was not
available), hypothyroidism, PA, and glucocorticoid use (current/
previous/never). Due to fat/bone effects of T4 and glucocortico-
ids, sensitivity analyses excluded thosewith current/previous ste-
roid use or hypothyroidism.Key resultswere gender-stratified to
assess interactions. To explore the bone-fat relationship, further
adjustments were made for variables potentially lying on a hy-
pothesized causal pathway (31). Data were managed using Mi-
crosoft Access (data entry checks; error rate .12%) and ana-
lyzed using Stata release 11 statistical software (StataCorp,
College Station, Texas).
Results
Participant characteristics
In total, 204 HBM cases (153 index cases, 49 affected
relatives, 2 affected spouses) and 126 family controls (89
unaffected relatives, 37unaffected spouses)were assessed.
HBM cases (age range, 26–87 y) were older than family
controls (19–88 y), were more commonly female and
postmenopausal, and had used estrogen replacement (Ta-
ble 1). Although weight was similar between HBM cases
and controls, HBM cases were shorter, and their BMIwas
higher. HBM cases were more likely to report a history of
cancer, steroid use, and hypothyroidism (Table 1). Dia-
betes mellitus was no more commonly reported among
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HBM cases than controls (20 [9.8%] vs 10 [7.9%], re-
spectively;P .6). Self-reported current and historical PA
levels were also similar. Controls, who were more com-
monly male, reported heavier alcohol intake than cases;
however, smoking status was similar. Only 2 HBM cases
were not of white European origin.
Comparison of metabolic phenotypes between
HBM cases and controls: unadjusted analyses
As expected, L1 and total hip sBMD, TB BMC, and TB
BMD were higher in HBM cases compared to controls
(Table 2). No evidence was detected to support a dispro-
portionate increase in skull BMD inHBMor apreferential
increase in lower-to-upper limb BMD (ie, noweight-bear-
ing effect), between HBM cases and controls (data not
shown).AlthoughTB%LMwas6.5%([95%CI4.6, 8.4];
P  .001) greater in controls in unadjusted analyses, TB
%FM was 6.2% ([4.2, 8.2]; P  .001) greater in HBM
cases. Osteocalcin levels were 9.4% lower in HBM cases
compared with controls (mean difference, 1.8 [0.2, 3.4]
g/L; P  .03), whereas P1NP, CTX, and adiponectin
were no different. When stratified by gender, the unad-
justed difference in TB FM between HBM cases and con-
trols was 2.8-fold greater in women (P  .02 for gender
interaction) (Table 3). Amongmen,HBMcases had lower
osteocalcin and CTX than controls.
Table 1. Clinical Characteristics of HBM Cases Compared With Family Controls
HBM Cases (n  204) Controls (n  126) P Value
Age, y 61.4 (13.9) 55.3 (16.1) .001
Height, cm 166.6 (9.1) 171.7 (10.5) .001
Weight, kg 85.6 (17.5) 84.6 (17.5) .604
BMI, kg/m2 30.8 (5.8) 28.8 (5.0) .001
Female 155 (76.0) 57 (45.2) .001
Postmenopausal 128 (82.6) 30 (52.6) .001
Estrogen replacement use (ever)a 78 (53.1) 10 (19.6) .001
Previous fractureb 78 (38.2) 62 (49.2) .051
Malignancy (ever)c 31 (15.2) 7 (5.6) .010
Steroid use (ever)d 50 (24.5) 20 (15.9) .064
Hypothyroidisme 27 (13.2) 2 (1.6) .002
Self-reported alcohol consumption .003
None 57 (27.9) 23 (18.3)
Occasional 23 (11.3) 10 (7.9)
Regular 104 (51.0) 62 (49.2)
Heavy 20 (9.8) 31 (24.6)
Self-reported smoking status .187
Never 84 (41.2) 65 (51.6)
Ex-smoker 96 (47.1) 48 (38.1)
Current 23 (11.3) 13 (10.3)
Current PA (IPAQ) (n  297) .645
Low 30 (14.7) 14 (11.1)
Moderate 72 (35.3) 42 (33.3)
High 84 (41.2) 55 (43.7)
Historical PA score (n  295)f .258
Very low (0–4) 22 (10.8) 13 (10.3)
Low (5–7) 35 (17.2) 28 (22.2)
Moderate (8–10) 37 (18.1) 28 (22.2)
High (11–14) 46 (22.5) 17 (13.5)
Very high (15–24) 44 (21.6) 25 (19.8)
Data are expressed as number (percent), except for age, height, weight, and BMI, which are expressed as mean (SD). Unadjusted P values from
regression models accounting for within-family clustering BMI were calculated as weight (kilograms)/height (meters2). Among both cases and
family controls, there was 1 report of hyperthyroidism and 2 of polycystic ovary syndrome.
a Postmenopausal estrogen replacement therapy.
b From any mechanism.
c Previous/current (HBM cases reported: 11 breast, 10 skin, 2 colon, 3 cervix, 2 renal, 2 endometrial, 1 each ovary, prostate, cerebral, thyroid,
leukemia. Controls reported: 3 skin, 2 breast, 1 prostate, 1 myeloma. Of 31 HBM cases with history of cancer, 25 were index cases and 6 (11.8%)
were relative/control cases.
d Previous (20 controls, 38 HBM) or current (no controls, 12 HBM cases), includes eye drops, intraarticular steroid injections, and oral steroids, eg,
for asthma, polymyalgia rheumatica, ulcerative colitis.
e Currently taking T4 replacement. Overall 51 (25%) HBM cases had 1 of the following: hyperthyroidism, hypothyroidism, celiac disease,
inflammatory bowel diseases, psoriasis, rheumatoid arthritis, vitiligo (42 were index cases), as did 5 (4%) controls. Autoimmune diseases are a
common indication for DXA scanning, and therefore index cases would be expected to have a higher prevalence of such disease.
f Constructed using best available evidence, grading PA between 0 (no PA) and 24 (very high PA) (17–19).
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We examined relationships between age and TB
BMC/FM stratified by gender (after minimal adjustment
for height only). In women, whereas TB BMC was sub-
stantially greater amongHBMcases compared to controls
at all ages, this difference increased with advancing age,
reflecting an inverse relationship between age and TB
BMC in controls, which was only weakly evident in HBM
cases (P  .02 for age interaction) (Figure 1). Among fe-
males, TB FM was similar in HBM cases and controls at
younger ages, but with increasing years it became pro-
gressively greater among HBM cases compared to con-
trols, reflecting an inverse association between age andTB
FM in controls (.02 [.004,.04]; P .01) not seen
among HBM cases (.0003 [.01, .01]; P  .96). How-
ever, evidence supporting this age interaction was weak
(P .15). By contrast inmen, no evidence was detected to
support an association between age and TB BMC/FM,
with the exception of a positive relationship between age
and TB FM in HBM cases (which only emerged after tak-
ing into account confounding by height).
Comparison of metabolic phenotypes between
HBM cases and controls: adjusted analyses
Adjustment for confounding factors (age, gender,
height, alcohol consumption, smoking status, malig-
nancy, steroid use, PA, hypothyroidism, and menopausal
status and estrogen replacement use in women) strength-
ened conclusions from unadjusted analyses, with the fol-
lowing exceptions: 1) among women, although LM was
now substantially higher in HBM cases compared to con-
trols (mean difference, 3.3 [1.2, 5.4] kg; P .002), the TB
%LM remained lower in HBM cases than controls (mean
difference, 4.5 [2.3, 6.8]%; P .001); and 2) now in both
men and women weak trends were seen toward lower
P1NP, osteocalcin, CTX, and adiponectin concentra-
tions in HBM cases compared with controls, which was
strongest for osteocalcin concentrations among females
(mean difference, .04 [.01, .09] g/L; P  .04) (Table 4).
Adjustment strengthened FM differences, with mean
%FM 4.2 (1.8, 6.6)% higher in female HBM cases com-
pared to controls (P  .001). Increases in FM seen in
women reflected a proportionately greater increase in cen-
tral obesity as indicated by greater android:gynoid and
trunk:peripheral fat ratios.
Using our regression model adjusted for all confound-
ers, we sequentially added further factors to investigate
potential causal pathways between fat and bone (Table 5).
If an association between exposure and outcome is atten-
uated by inclusion of a factor in the regression model, this
Table 2. Unadjusted DXA-Measured Body Composition and Bone Turnover Markers in HBM Cases Compared With
Family Controls
HBM, Mean (SD) Control, Mean (SD)
Mean difference
(95% CI) P Value
Spine and hip DXA (n  330)
L1 sBMD, g/cm2 1.40 (0.16) 1.07 (0.16) 0.33 (0.29, 0.36) .001
Total hip sBMD, g/cm2 1.25 (0.18) 0.99 (0.14) 0.25 (0.21, 0.28) .001
TB DXA (n  330)
BMD,a g/cm2 1.36 (0.13) 1.24 (0.12) 0.12 (0.09, 0.15) .001
BMC, kga 3.48 (0.69) 3.16 (0.65) 0.32 (0.17, 0.46) .001
LM, kg 47.0 (10.3) 51.4 (11.4) 4.34 (6.72, 1.97) .001
FM, kg 35.6 (12.6) 29.8 (11.3) 5.83 (3.35, 8.32) .001
% bone massa 4.0 (0.7) 3.7 (0.6) 0.3 (0.2, 0.4) .001
% LM 55.3 (8.9) 61.8 (8.7) 6.5 (8.4, 4.6) .001
% FM 40.7 (9.3) 34.5 (9.1) 6.2 (4.2, 8.2) .001
FM phenotype (n  330)
Android, kg 3.45 (1.40) 3.01 (1.26) 0.44 (0.16, 0.71) .002
Gynoid, kg 5.70 (1.85) 4.98 (1.82) 0.72 (0.33, 1.10) .001
Android:gynoid ratio 0.60 (0.18) 0.59 (0.20) 0.00 (0.04, 0.04) .906
Trunk, kg 19.5 (6.74) 16.7 (6.23) 2.84 (1.51, 4.17) .001
Trunk:peripheral ratiob 1.18 (0.59) 1.28 (0.62) 0.11 (0.21, 0.00) .046
Bone turnover markers and
adiponectin (n  326)
P1NP, g/L 36.1 (17.9) 38.1 (18.8) 1.96 (5.90, 1.98) .329
Osteocalcin (total), g/L 17.5 (7.20) 19.3 (7.48) 1.81 (3.42, 0.19) .028
CTX, g/L 0.21 (0.13) 0.22 (0.13) 0.02 (0.04, 0.01) .281
Adiponectin (total), g/L 6.61 (3.79) 6.55 (3.56) 0.06 (0.77, 0.89) .893
Mean (SD) L1 Z-scores were 3.9 (1.3) and 0.5 (1.2), and total hip Z-scores were 3.0 (1.2) and 0.6 (0.9) in HBM cases and controls, respectively.
Similar proportions of HBM cases and controls were scanned on Lunar Prodigy DXA scanners, 175 (86%) and 112 (90%), respectively (P  0.4).
a Adjusted for metallic artifact.
b Peripheral  (right  left arms)  (right  left legs).
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implies that the factor may lie on the causal pathway (31).
Differences in TB FM observed between HBM cases and
controlswere fully attenuatedby conditioningon total hip
sBMDandpartially attenuatedby conditioningonTBLM
and TB BMD, whereas adjustment for L1 sBMD, bone
turnover markers, or adiponectin had little or no impact.
Differences in LM between HBM cases and controls were
fully attenuated by adjustment for TB FM. In contrast, the
Table 3. Unadjusted DXA Measured Body Composition and Bone Turnover Markers in HBM Cases Compared With
Family Controls, Stratified by Gender
Women (n  212) Men (n  118)
HBM, Mean
(95% CI)
Control, Mean
(95% CI)
Mean difference
(95% CI) P Value
HBM, Mean
(95% CI)
Control, Mean
(95% CI)
Mean Difference
(95% CI) P Value
Spine and hip DXA
L1 sBMD, g/cm2 1.37 (1.35, 1.39) 1.04 (1.00, 1.08) 0.33 (0.29, 0.38) .001 1.49 (1.45, 1.54) 1.11 (1.07, 1.15) 0.38 (0.32, 0.44) .001
Total hip sBMD, g/cm2 1.22 (1.20, 1.24) 0.94 (0.90, 0.97) 0.28 (0.24, 0.32) .001 1.34 (1.28, 1.39) 1.05 (1.00, 1.10) 0.29 (0.23, 0.35) .001
TB DXA
BMD,a g/cm2 1.31 (1.29, 1.33) 1.15 (1.13, 1.18) 0.16 (0.12, 0.19) .001 1.43 (1.39, 1.46) 1.27 (1.24, 1.31) 0.15 (0.11, 0.19) .001
BMC, kga 3.18 (3.11, 3.26) 2.60 (2.48, 2.72) 0.59 (0.46, 0.72) .001 4.04 (3.85, 4.23) 3.55 (3.36, 3.73) 0.49 (0.30, 0.69) .001
LM, kg 42.8 (41.7, 44.0) 42.0 (40.2, 43.8) 0.83 (1.05, 2.70) .389 59.3 (56.9, 61.6) 59.5 (57.4, 61.7) 0.26 (3.19, 2.67) .862
FM, kg 37.6 (35.4, 39.8) 32.5 (29.0, 35.9) 5.17 (1.54, 8.80) .005b 28.5 (25.9, 31.1) 26.6 (24.4, 28.9) 1.86 (1.48, 5.20) .274b
% bone massa 3.9 (3.8, 4.1) 3.5 (3.3, 3.7) 0.4 (0.2, 0.6) .001 4.5 (4.3, 4.7) 4.0 (3.8, 4.2) 0.5 (0.3, 0.7) .001
% LM 52.1 (50.9, 53.4) 55.9 (54.0, 57.8) 3.8 (5.7, 1.8) .001 65.1 (63.2, 67.1) 67.0 (65.3, 68.8) 1.9 (4.3, 0.5) .124
% FM 44.0 (42.7, 45.3) 40.6 (38.6, 42.7) 3.3 (1.3, 5.4) .001 30.4 (28.4, 32.4) 29.0 (27.3, 30.8) 1.4 (1.1, 3.9) .284
FM phenotype
Android, kg 3.49 (3.25, 3.74) 2.84 (2.45, 3.24) 0.65 (0.24, 1.06) .001 3.23 (2.89, 3.56) 2.98 (2.70, 3.27) 0.24 (0.18, 0.67) .258
Gynoid, kg 6.10 (5.78, 6.42) 5.72 (5.21, 6.22) 0.38 (0.14, 0.91) .001 4.35 (3.94, 4.77) 4.18 (3.81, 4.55) 0.18 (0.33, 0.69) .495
Android:gynoid ratio 0.55 (0.53, 0.58) 0.47 (0.42, 0.51) 0.09 (0.04, 0.13) .001b 0.72 (0.67, 0.77) 0.70 (0.66, 0.74) 0.02 (0.05, 0.08) .605b
Trunk, kg 20.0 (18.9, 21.2) 16.4 (14.6, 18.3) 3.60 (1.68, 5.53) .001 17.5 (15.8, 19.1) 16.2 (14.8, 17.7) 1.22 (0.85, 3.30) .249
Trunk:peripheral ratiob 1.10 (1.02, 1.19) 0.94 (0.83, 1.05) 0.17 (0.07, 0.26) .001b 1.47 (1.28, 1.65) 1.54 (1.36, 1.72) 0.07 (0.25, 0.10) .405b
Bone turnover markers
and adiponectina
P1NP, g/L 37.1 (34.0, 40.1) 38.3 (33.2, 43.4) 1.24 (6.84, 4.37) .665 33.7 (28.2, 39.1) 37.6 (32.5, 42.6) 3.88 (10.1, 2.32) .220
Osteocalcin
(total), g/L
18.0 (16.8, 19.2) 19.6 (17.6, 21.6) 1.58 (3.90, 0.75) .184 16.4 (14.3, 18.4) 19.4 (17.5, 21.2) 3.01 (5.34, 0.68) .011
CTX, g/L 0.22 (0.19, 0.24) 0.22 (0.18, 0.26) 0.01 (0.05, 0.04) .783 0.17 (0.14, 0.20) 0.22 (0.19, 0.25) 0.05 (0.09, 0.01) .017
Adiponectin
(total), g/L
7.06 (6.42, 7.70) 7.81 (6.75, 8.88) 0.75 (1.99, 0.49) .237 5.15 (4.40, 5.89) 5.54 (4.92, 6.16) 0.39 (1.36, 0.58) .432
a n  209 women and 107 men.
b Gender interaction, P  .05.
Figure 1. Differences in TB BMC and FM with increasing age in HBM cases and controls, stratified by gender. Gray triangles, HBM cases; black
circles, controls. B coefficients are standardized and adjusted for height only with 95% CI shown.
J Clin Endocrinol Metab, February 2013, 98(2):818–828 jcem.endojournals.org 823
differences in BMD, measured at any site, were only min-
imally attenuatedby conditioningonTBFM,adiponectin,
and/or bone turnover markers.
Sensitivity analyses
Sensitivity analyses were performed in males and fe-
males combinedwithourmodel adjusted for all confound-
ers (Supplemental Table 4). First, excluding current/pre-
vious steroid use (n  70) and hypothyroidism (n  29)
did not materially affect point estimates (Supplemental
Tables 5 and 6). Second,when restricting to those scanned
by Lunar DXA, although absolute DXA values were mar-
ginally lower, results were no different from those ob-
tained after combining Lunar and Hologic data using
standardization formulae (Supplemental Table 7). In
menopause-stratified analyses, although premenopausal
women were fewer, differences in FM observed between
HBM cases and controls were more evident among post-
menopausal women, in whomHBMcases had greater an-
droid, gynoid, and trunk fat. As expected, bone turnover
markers were higher among postmenopausal than pre-
menopausalwomen (SupplementalTable8) (small sample
size constrained full adjustment for PA). The higher prev-
alence of prior cancer was investigated by restricting anal-
yses to relatives and spousesonly (ie, excluding index cases
who may have been biased by DXA referral indication).
Compared with 7 (5.6%) controls with a cancer history,
6 (11.8%) relative/spouse HBM cases reported a cancer
history (P  .152); most (n  25) reported that cancer
occurred within the HBM index cases.
Discussion
We examined a population with unexplained extreme
HBM, characterized by a mild skeletal dysplasia (14), to
investigate the relationship between elevated BMD and
BMI.We found that in HBMwomen FM is elevated, with
a particular tendency toward central adiposity. HBM
cases are thought to have a genetic predisposition to their
raised BMD, suggesting a causal pathway whereby raised
BMD leads to increased FM. Several observations support
a primary bone phenotype with secondary fat effects (14).
For example, although substantial, the observed FM ele-
vation in HBM cases was less marked than their BMD
increase (0.5 and 1.5 SD increases in TB FM and BMD in
HBMcases compared to controls, respectively). Secondly,
in regression analyses, FM differences between HBM
cases and controls were attenuated by BMD adjustment;
conversely, BMD differences were not attenuated by FM
Table 4. Adjusted DXA-Measured Body Composition and Bone Turnover Markers in HBM Cases Compared With
Family Controls, Stratified by Gender
Women (n  212) Men (n  118)
HBM, Mean
(95%CI)
Control, Mean
(95% CI)
Mean Difference
(95% CI) P Value
HBM, Mean
(95% CI)
Control, Mean
(95% CI)
Mean Difference
(95% CI) P Value
Spine and hip DXA
L1 sBMD, g/cm2 1.40 (1.32, 1.49) 1.05 (0.96, 1.13) 0.36 (0.31, 0.41) .001 1.61 (1.45, 1.77) 1.19 (1.03, 1.35) 0.42 (0.34, 0.49) .001
Total hip sBMD,
g/cm2
1.16 (1.08, 1.24) 0.87 (0.79, 0.95) 0.29 (0.24, 0.34) .001d 1.39 (1.21, 1.57) 1.03 (0.85, 1.20) 0.37 (0.29, 0.44) .001d
TB DXA
BMD,a g/cm2 1.35 (1.29, 1.42) 1.18 (1.12, 1.24) 0.18 (0.14, 0.21) .001 1.42 (1.30, 1.55) 1.22 (1.10, 1.35) 0.20 (0.15, 0.25) .001
BMC, kga 3.33 (3.10, 3.55) 2.67 (2.46, 2.89) 0.65 (0.53, 0.78) .001 3.82 (3.25, 4.38) 3.02 (2.46, 3.58) 0.80 (0.57, 1.03) .001
LM, kg 48.1 (44.5, 51.8) 44.8 (41.3, 48.3) 3.31 (1.22, 5.39) .002 55.0 (48.5, 61.5) 52.7 (46.3, 59.2) 2.22 (0.44, 4.89) .102
FM, kg 42.3 (35.0, 49.6) 33.4 (26.5, 40.4) 8.88 (4.73, 13.0) .001d 29.7 (20.5, 38.9) 26.9 (17.8, 36.0) 2.77 (1.30, 6.85) .183d
% bone massa 3.7 (3.3, 4.2) 3.4 (3.0, 3.9) 0.3 (0.01, 0.5) .039 4.4 (3.8, 5.0) 3.8 (3.2, 4.4) 0.6 (0.3, 0.8) .001
% LM 52.6 (48.6, 56.5) 57.1 (53.3, 60.9) 4.5 (6.8, 2.3) .001 62.4 (55.5, 69.4) 64.3 (57.4, 71.3) 1.9 (4.9, 1.1) .216
% FM 43.6 (39.4, 47.8) 39.4 (35.4, 43.4) 4.2 (1.8, 6.6) .001 33.3 (26.1, 40.4) 32.0 (24.9, 39.0) 1.3 (1.8, 4.4) .417
FM phenotype
Android, kg 4.07 (3.23, 4.90) 3.07 (2.27, 3.87) 1.00 (0.53, 1.47) .001d 3.33 (2.22, 4.45) 2.99 (1.88, 4.09) 0.35 (0.13, 0.83) .154d
Gynoid, kg 6.50 (5.44, 7.56) 5.81 (4.79, 6.83) 0.69 (0.09, 1.29) .025 4.67 (3.24, 6.09) 4.14 (2.73, 5.56) 0.52 (0.08, 1.12) .087
Android:gynoid ratio 0.58 (0.49, 0.67) 0.46 (0.37, 0.54) 0.12 (0.07, 0.17) .001d 0.68 (0.52, 0.83) 0.70 (0.54, 0.85) 0.02 (0.09, 0.04) .477d
Trunk, kg 22.6 (18.8, 26.4) 17.3 (13.6, 20.9) 5.31 (3.16, 7.47) .001d 18.4 (12.9, 24.0) 16.5 (11.0, 22.1) 1.89 (0.56, 4.34) .131d
Trunk:peripheral ratiob 1.11 (0.88, 1.35) 0.91 (0.69, 1.13) 0.20 (0.08, 0.33) .001d 1.35 (0.79, 1.91) 1.37 (0.80, 1.93) 0.02 (0.22, 0.19) .867d
Bone turnover markers
and adiponectinc
P1NP, g/L 25.3 (13.7, 37.0) 30.3 (19.0, 41.6) 5.01 (11.8, 1.73) .145 42.3 (22.1, 62.5) 46.5 (26.3, 66.7) 4.21 (12.3, 3.85) .306
Osteocalcin (total), g/L 14.0 (9.34, 18.7) 16.8 (12.3, 21.4) 2.79 (5.51, 0.07) .044 19.5 (12.5, 26.5) 21.8 (14.8, 28.8) 2.33 (5.10, 0.45) .101
CTX, g/L 0.15 (0.06, 0.23) 0.19 (0.11, 0.27) 0.04 (0.09, 0.01) .093 0.28 (0.16, 0.40) 0.33 (0.21, 0.45) 0.05 (0.10, 0.01) .079
Adiponectin (total), g/L 5.55 (3.36, 7.75) 6.60 (4.47, 8.74) 1.05 (2.32, 0.22) .106 4.29 (1.77, 6.81) 4.60 (2.11, 7.09) 0.31 (1.35, 0.73) .559
a Adjusted for metallic artifact.
b Peripheral  (right  left arms)  (right  left legs).
c n  209 women and 107 men. Adjusted for age, gender, height, alcohol consumption, smoking status, malignancy and steroid use, current and
historical PA, hypothyroidism, and menopausal status and estrogen replacement use in women (continuous variables centered for adjustment).
d Gender interaction, P  .05.
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Table 5. Regression Models Investigating the Hypothesized Causal Relationships Between Body Composition
Parameters in HBM Cases and Controls, Stratified by Gender
Outcome/Additional
Factor Adjustment
Women (n  212) Men (n  118)
P valueb
SD Difference in
Outcome Between HBM
Cases and Controls (95% CI) P value
SD Difference in
Outcome Between HBM
Cases and Controls (95% CI) P value
TB FM
Adjusted modela 0.71 (0.38, 1.04) .001 0.22 (0.10, 0.55) .183 .078
 TB LM 0.31 (0.06, 0.57) .015 0.18 (0.15,0.50) .283 .076
 L1 sBMD 0.58 (0.09, 1.06) .019 0.13 (0.64, 0.38) .618 .053
 Total Hip
sBMD
0.15 (0.30, 0.59) .524 0.14 (0.61, 0.33) .552 .026
 TB BMDc 0.32 (0.10, 0.74) .130 0.21 (0.60, 0.18) .297 .052
 Adiponectin 0.61 (0.27, 0.94) .001 0.22 (0.11, 0.55) .195 .146
 P1NP, OC,
CTX
0.69 (0.34, 1.03) .001 0.19 (0.15, 0.53) .273 .084
TB LM
Adjusted modela 0.30 (0.11, 0.49) .002 0.20 (0.04, 0.45) .102 .948
 TB FM 0.05 (0.10, 0.19) .536 0.15 (0.09, 0.40) .226 .484
 Adiponectin 0.26 (0.03, 0.42) .022 0.23 (0.03, 0.48) .078 .819
 P1NP, OC,
CTX
0.29 (0.09, 0.49) .004 0.24 (0.03, 0.51) .083 .930
 TB FM,
adiponectin,
P1NP, OC,
CTX
0.05 (0.11, 0.20) .572 0.22 (0.06, 0.50) .117 .435
L1 sBMD
Adjusted modela 1.54 (1.33, 1.75) .001 1.79 (1.49, 2.10) .001 .115
 TB FM 1.53 (1.30, 1.75) .001 1.76 (1.45, 2.06) .001 .077
 Adiponectin 1.54 (1.32, 1.76) .001 1.81 (1.50, 2.12) .001 .082
 P1NP, OC,
CTX
1.52 (1.30, 1.74) .001 1.80 (1.47, 2.12) .001 .086
 TB FM,
adiponectin,
P1NP, OC,
CTX
1.52 (1.28, 1.76) .001 1.80 (1.47, 2.13) .001 .061
Total hip sBMD
Adjusted modela 1.42 (1.19, 1.64) .001 1.79 (1.42, 2.17) .001 .098
 TB FM 1.27 (1.04, 1.51) .001 1.73 (1.35, 2.10) .001 .035
 Adiponectin 1.34 (1.10, 1.57) .001 1.80 (1.42, 2.18) .001 .052
 P1NP, OC,
CTX
1.38 (1.14, 1.62) .001 1.79 (1.40, 2.18) .001 .072
 TB FM,
adiponectin,
P1NP, OC,
CTX
1.22 (0.98, 1.46) .001 1.68 (1.29, 2.06) .001 .031
TB BMDa
Adjusted modela 1.28 (1.02, 1.54) .001 1.47 (1.09, 1.86) .001 .461
 TB FM 1.15 (0.89, 1.42) .001 1.38 (1.01, 1.75) .001 .233
 Adiponectin 1.24 (0.97, 1.50) .001 1.49 (1.11, 1.88) .001 .312
 P1NP, OC,
CTX
1.25 (0.99, 1.52) .001 1.45 (1.05, 1.85) .001 .412
 TB FM,
adiponectin,
P1NP, OC,
CTX
1.14 (0.86, 1.41) .001 1.39 (0.99, 1.79) .001 .216
SD difference in outcome between cases and controls using the model adjusted for all confounders  additional factors potentially lying on a
bone-fat causal pathway.
a Confounders in adjusted model: age, gender, height, alcohol consumption, smoking status, malignancy, steroid use, current and historical PA,
hypothyroidism, estrogen replacement use, and years post menopause in women (continuous variables centered for adjustment).
b P value for gender interaction.
c Adjusted for metallic artifact.
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adjustment. Although absolute LM was greater among
HBM cases than controls (by .25 SD), this was explained
by observed FM differences; relative to bone and FM in-
creases, female HBM cases had disproportionately re-
duced LM. Although a higher proportion of HBM cases
had hypothyroidism and current/previous glucocorticoid
use, the latter possibly reflecting the original indication for
DXA scanning index cases, this did not explain their
higher FM.
Our findings are consistent with those from an ex-
tended Danish family with extremely elevated bone mass,
due to activating T253I LRP5 mutations, found to have
elevated FM (11). However, normal BMIs have also been
described in both M282V and G512T LRP5 HBM and
sclerosteosis due to SOSTmutations (32–36), possibly re-
flecting differences in gender, age, and small study num-
bers. Our findings supporting a primary bone phenotype
with secondary FM changes conflict with our previous
Mendelian randomization analysis in adolescents in AL-
SPAC, which suggested a causal influence of obesity on
BMD (11).One explanation is a bidirectional causal path-
way between fat and bone, with the effects of bone on fat
prevailing in individuals with extreme BMD elevations.
Alternatively, rather than a physiological relationship
between bone and FM, genetic pleiotropy, whereby mu-
tations affect both BMD and FM, could explain our find-
ings as well as monogenic LRP5HBMFM increases (11),
given the role of wnt signaling pathways in adipogenesis
(37). Although direct sequencing of exons 2, 3, and 4 has
identified anabolic LRP5 mutations in  2% of HBM
cases (32), other HBM-causing genes, yet to be identified,
may also contribute to adipogenesis. Of note, CLCN7
mutations causing autosomal dominant osteopetrosis
(ADOII) seem a less likely pleiotropic cause, first, because
raised BMI has not been a reported feature of ADOII (38,
39), and second, because previous radiological evaluation
of all our HBM cases has not shown any characteristics of
ADOII (14).
Theclinical implicationsof elevatedFMinHBMmayrelate
to establishedcomplicationsofobesity, suchas type IIdiabetes,
particularly because central adiposity increases insulin resis-
tance risk (40). Furthermore, disproportionately low LM in
HBMmayreflectsarcopenicobesity(41).Trunkfat,aproxyfor
visceral fat (42), has been associatedwith dyslipidemia and in-
sulin resistance (43, 44); however, our studywas not powered
to detect metabolic and cardiovascular health outcomes. Fur-
therstudiestodirectlyevaluateinsulinresistanceareplanned,as
are those to assess muscle function.
Determining the direction of causality between bone
and fat in HBM cases aids mechanistic understanding of
bone-fat pathways. Currently, the genetic basis underly-
ing the great majority of our HBM cases is unknown (32).
Givenphenotypic similarities betweenourHBMcases and
those with established activating LRP5 mutations, one
might expect enhanced osteoblast function and elevated
bone formation markers in HBM when the phenotype is
developing (eg, during puberty). Consistent with this
view, recent peripheral quantitative computed tomogra-
phy evaluation has shown greater tibial and radial cross-
sectional area in HBM, which is likely to reflect enhanced
periosteal apposition secondary to increased osteoblast
activity (45). Yet LRP5HBM case reports/series have re-
ported low, normal, and high turnover (12, 32–34, 46,
47). In our study, bone turnover markers, including os-
teocalcin, tended to be lower among HBM cases (4 cases
with specificLRP5mutations had either normal or higher
turnover). It may be that the same mechanisms initially
responsible for gaining higher bonemass then lead to sup-
pression of bone turnover once HBM is achieved, thereby
ensuring that HBM is maintained in later life.
Rodent studies point toward a pathway of reduced
bone turnover resulting in decreased osteocalcin, associ-
ated with lower adiponectin, impaired insulin sensitivity,
and increased fat deposition due to reduced energy expen-
diture (6). We explored whether a similar mechanism
might explain the elevated FM observed in our HBM
cases. Bone turnover sampled at a single time point may
not reflect accumulated exposure over the life course,
whichweareunable tomeasure.Nevertheless, on thebasis
of our results suggesting that 1) bone turnover tends to be
suppressed once HBM is established, and 2) higher FM in
HBM cases is age-dependent, our findings are consistent
with an equivalent causal pathwaybetweenbone turnover
and energy metabolism to that seen in rodents. However,
conversely, FM differences between HBM cases and con-
trols were not attenuated by adjustment for bone turn-
over. Differences in FM between HBM cases and controls
were attenuated by adjustment for hip but not lumbar
spine BMD, potentially reflecting a preferential cortical
bone-fat relationship. Cortical bone influencing fat me-
tabolism may reflect a cortical-derived factor, eg, scleros-
tin, which was recently found to be positively related to
FM in postmenopausal women (48).
We observed large FM differences betweenHBM cases
and controls in women but not men, particularly post-
menopausal women, suggesting a possible interaction be-
tween BMD, FM, and sex steroid deficiency. This appar-
ent sex interaction is hard to explain, particularly in light
of recent evidence that osteocalcin acts as a testosterone
regulator in men, which might be expected to exert sec-
ondary effects on body composition (49). However, we
also observed a trend toward increasing FMdifferences in
women according toHBMstatuswith age.Hence, despite
adjustment, it is difficult to determine whether the greater
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FM elevation of postmenopausal HBM cases simply re-
flects their greater age as opposed to duration of estrogen
deficiency.
Limitations
A key limitation is our current lack of longitudinal data,
limiting conclusions regarding directions of causality. Rela-
tive/spouse controls were considered to be appropriate con-
trols because 1) they share common environmental factors
with cases that would otherwise be difficult to measure and
control for as confounding factors; 2) their inclusion aids
futuregenetic studiesbecause itpermits theuseofmorepow-
erful family-based analyses; and 3) they had appropriate
BMD (Table 2). However, because controls were recruited
fromwithin families, they are likely to have been more sim-
ilar to HBM cases than unrelated general population con-
trols; hence, clustered analyses were performed to account
for the lack of statistical independence due to within-family
clustering of environmental factors and shared genotypes.
Despite this, our reporteddifferencesmaystill underestimate
the true magnitude of the HBM phenotype, than would
HBM cases if compared with general population controls.
Considering referral indications for clinical DXA services,
ourstudydesignmost likelyaccounts fordifferencesbetween
cases and controls in gender, postmenopausal status, estro-
gen replacement, steroid use, and prior history of malig-
nancy. For example, index cases were more often 1) female,
hence heterosexual partner controls were more often male;
and2) postmenopausal, andhence their children rather than
their parentsmore often participated, explaining the age dif-
ference between cases and controls. Although fewer men
were sampled, adjusted FM analyses still had 89.6% power
( .05) todetect theobserveddifferencebetweencases and
controls. Although we collected data regarding a range of
potential confounders, residual confounding cannot be ex-
cluded, particularly considering the differences in clinical
characteristics betweenHBM cases and controls. Due to lo-
gistical limitations, CTXwas sampled without controlling
for possible effects of diurnal variation or food ingestion;
however, bias would be expected to be nondifferential.
Conclusions
To investigate causal pathways between bone and fat,
we conducted a case-control study of body composition
and bone turnover in a UK-based population of HBM
cases in whom BMD is thought to be markedly increased
as a result of a primary genetic cause. We found that,
compared with controls, TB FM was on average 9 kg
higher in female HBM cases, in whom FM remained con-
stant with age, in contrast to an inverse association ob-
served among controls. Differences in FM observed be-
tween HBM cases and controls were explained by
adjustment for BMD, but not by bone turnover; the latter
being modestly reduced in HBM. In contrast, the greater
BMD of female HBM cases compared with controls was
not attenuated by adjustment for FM. We conclude that
HBM is associated with greater FM, reflecting either ge-
netic pleiotropic effects or supporting, within the context
of an extreme bone phenotype, a causal pathway between
bone mass and FM that is independent of bone turnover.
Further studies are justified to explore the mechanisms
involved and to determine their impact on insulin resis-
tance and other metabolic health outcomes.
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